Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02281019




Registration number
NCT02281019
Ethics application status
Date submitted
9/10/2014
Date registered
2/11/2014
Date last updated
10/07/2019

Titles & IDs
Public title
SpyGlass AMEA Registry
Scientific title
Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System (DVS) Throughout the AMEA (Asia, Middle-East, Africa) Region
Secondary ID [1] 0 0
90947376
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Biliary Stricture 0 0
Biliary Obstruction Due to Common Bile Duct Stone 0 0
Periampullary Tumor 0 0
Hemobilia 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Observational [Patient Registry]
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Surgery - ERCP (Endoscopic Retrograde Cholangiopancreatography)
Treatment: Devices - SpyGlass DVS and SpyGlass Digital Simple (DS)

Indeterminate strictures or undefined filling defects -

Biliary stone cases -

Other indications -


Treatment: Surgery: ERCP (Endoscopic Retrograde Cholangiopancreatography)
ERCP procedure will be performed to visualize bile ducts.

Treatment: Devices: SpyGlass DVS and SpyGlass Digital Simple (DS)
Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
Intervention code [1] 0 0
Treatment: Surgery
Intervention code [2] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Procedural success for indeterminate strictures or undefined filling defects
Timepoint [1] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours
Primary outcome [2] 0 0
Procedural success for biliary stone cases
Timepoint [2] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours
Primary outcome [3] 0 0
Procedural success for other indications
Timepoint [3] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours
Secondary outcome [1] 0 0
Evaluation of serious adverse events (SAEs) related to the SpyGlass devices and/or the SpyGlass procedure
Timepoint [1] 0 0
Procedure from enrollment through the 72 Hour Post Procedure Follow-up Visit
Secondary outcome [2] 0 0
Impact of SpyGlass procedure on suspected diagnosis based on prior ERCP
Timepoint [2] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours
Secondary outcome [3] 0 0
Evaluation of impact of use of antibiotics on incidence of SAEs related to the device and/or procedure.
Timepoint [3] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours
Secondary outcome [4] 0 0
For patients undergoing SpyBite biopsy: correlation between number of biopsies and conclusive histopathology of SpyBite biopsies.
Timepoint [4] 0 0
Procedure to 6 months
Secondary outcome [5] 0 0
For patients undergoing stone management: number of SpyGlass procedures needed to reach stone clearance.
Timepoint [5] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours
Secondary outcome [6] 0 0
For patients undergoing stone management: correlation between stone size and ability to reach stone clearance in one SpyGlass session.
Timepoint [6] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours
Secondary outcome [7] 0 0
For patients undergoing stone management: incidence of visualization of stones not suspected during previous ERCP.
Timepoint [7] 0 0
Procedure - the average expected duration of the procedure is 1.5 hours

Eligibility
Key inclusion criteria
* Age 18 or older.
* Willing and able to provide written informed consent to participate in the study.
* Willing and able to comply with the study procedures.
* Indicated for ERCP and cholangioscopy or indicated for ERCP with suspected need for cholangioscopy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Endoscopic techniques are contraindicated.
* ERCP is contraindicated
* A medical condition that warrants the use of the device outside of the indication for use.
* Requirement for anticoagulation that cannot be safely stopped at least 7 days prior to the procedure.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/10/2016
Sample size
Target
Accrual to date
Final
526
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
Royal Prince Alfred Hospital - Newtown
Recruitment postcode(s) [1] 0 0
4029 - Herston
Recruitment postcode(s) [2] 0 0
- Adelaide
Recruitment postcode(s) [3] 0 0
- Newtown
Recruitment outside Australia
Country [1] 0 0
Hong Kong
State/province [1] 0 0
Shatin
Country [2] 0 0
India
State/province [2] 0 0
West Bengal
Country [3] 0 0
India
State/province [3] 0 0
Chandigarh
Country [4] 0 0
India
State/province [4] 0 0
Gurgaon
Country [5] 0 0
India
State/province [5] 0 0
Hyderabad
Country [6] 0 0
India
State/province [6] 0 0
Parel
Country [7] 0 0
Japan
State/province [7] 0 0
Kawasaki
Country [8] 0 0
Japan
State/province [8] 0 0
Osaka-sayama
Country [9] 0 0
Japan
State/province [9] 0 0
Tokyo
Country [10] 0 0
Korea, Republic of
State/province [10] 0 0
Bucheon
Country [11] 0 0
Korea, Republic of
State/province [11] 0 0
Seoul
Country [12] 0 0
Pakistan
State/province [12] 0 0
Karachi
Country [13] 0 0
Saudi Arabia
State/province [13] 0 0
Riyadh
Country [14] 0 0
Singapore
State/province [14] 0 0
Singapore
Country [15] 0 0
South Africa
State/province [15] 0 0
Centurion
Country [16] 0 0
Thailand
State/province [16] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boston Scientific Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Benedict Devereaux
Address 0 0
Royal Brisbane and Women's Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02281019